Get the Stockscreener App
32.47
0.98%
-0.32
After Hours:
32.47
Staar Surgical Co stock is traded at $32.47, with a volume of 710.28K.
It is down -0.98% in the last 24 hours and up +30.93% over the past month.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
See More
Previous Close:
$32.79
Open:
$32.72
24h Volume:
710.28K
Relative Volume:
0.56
Market Cap:
$1.62B
Revenue:
$239.44M
Net Income/Loss:
$-80.45M
P/E Ratio:
-19.92
EPS:
-1.6303
Net Cash Flow:
$-40.05M
1W Performance:
+1.25%
1M Performance:
+30.93%
6M Performance:
+15.96%
1Y Performance:
+72.99%
1-Day Range:
$32.47
$33.32
1-Week Range:
$31.16
$33.57
52-Week Range:
$15.59
$35.87
Staar Surgical Co Stock (STAA) Company Profile
Name
Staar Surgical Co
Sector
Industry
Phone
(626) 303-7902
Address
1911 WALKER AVE, MONROVIA, CA
Compare STAA vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STAA
Staar Surgical Co
|
32.47 | 1.63B | 239.44M | -80.45M | -40.05M | -1.6303 |
ISRG
Intuitive Surgical Inc
|
438.10 | 155.76B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
147.63 | 40.30B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.78 | 33.13B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
37.01 | 31.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
208.05 | 30.31B | 5.54B | 1.52B | 1.74B | 10.37 |
Staar Surgical Co Stock (STAA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-03-26 | Initiated | Wedbush | Neutral |
| Jan-16-26 | Resumed | Morgan Stanley | Underweight |
| Apr-21-25 | Initiated | Wells Fargo | Equal Weight |
| Feb-12-25 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-12-25 | Downgrade | Jefferies | Buy → Hold |
| Feb-12-25 | Downgrade | Mizuho | Outperform → Neutral |
| Feb-12-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-15-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-11-24 | Upgrade | BTIG Research | Neutral → Buy |
| Mar-11-24 | Upgrade | Stifel | Hold → Buy |
| Dec-05-23 | Downgrade | Needham | Buy → Hold |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-15-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-03-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-07-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-17-23 | Initiated | Piper Sandler | Neutral |
| Feb-06-23 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-28-22 | Reiterated | BTIG Research | Buy |
| Dec-08-22 | Initiated | Stifel | Hold |
| Nov-07-22 | Upgrade | Sidoti | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-28-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jul-09-21 | Initiated | Oppenheimer | Perform |
| Jan-19-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-26-20 | Downgrade | Sidoti | Buy → Neutral |
| Aug-31-20 | Upgrade | Sidoti | Neutral → Buy |
| Aug-06-20 | Reiterated | The Benchmark Company | Buy |
| Jul-06-20 | Downgrade | Sidoti | Buy → Neutral |
| Jun-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-15-20 | Initiated | Jefferies | Buy |
| Dec-04-19 | Initiated | BTIG Research | Buy |
| Sep-24-18 | Reiterated | The Benchmark Company | Buy |
| Aug-06-18 | Resumed | The Benchmark Company | Buy |
| Nov-20-17 | Reiterated | The Benchmark Company | Buy |
| Aug-14-17 | Reiterated | The Benchmark Company | Buy |
| Mar-03-17 | Reiterated | The Benchmark Company | Buy |
| May-18-16 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-13 | Resumed | The Benchmark Company | Buy |
| Feb-28-13 | Reiterated | The Benchmark Company | Buy |
| Nov-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-02-12 | Initiated | Northland Securities | Outperform |
| Oct-25-11 | Reiterated | The Benchmark Company | Buy |
| Oct-12-10 | Initiated | Morgan Joseph | Buy |
| May-11-10 | Initiated | Benchmark | Buy |
View All
Staar Surgical Co Stock (STAA) Latest News
What's Driving Broadwood Partners' Deep Dive into STAAR Surgical - Kavout
Midday Stock Roundup: Glaukos Corp. Shares Drop 11% - Orange County Business Journal
5 must-read analyst questions from STAAR Surgical’s Q1 earnings call - MSN
Vision-correction lens maker STAAR hosts May investor talks - Stock Titan
5 Must-Read Analyst Questions From STAAR Surgical’s Q1 Earnings Call - Yahoo Finance
STAAR Surgical signals standalone strength as Alcon overhang fades after strong Q1 - Investing.com Nigeria
STAAR Surgical (STAA) Q1 2026 Earnings Transcript - AOL.com
STAAR Surgical Q1 2026 Results: Revenue Up 120%, EPS Beats EstimatesNews and Statistics - IndexBox
STAAR Surgical (STAA) interim Co-CEO receives PSUs and share tax withholding - Stock Titan
STAAR Surgical (STAA) interim co-CEO reports PSU vesting and tax withholding - Stock Titan
STAAR Surgical (STAA) CDO logs PSU vesting, tax-withheld shares and new holdings - Stock Titan
STAA Q1 Deep Dive: China Momentum, Cost Discipline, and Stabilized Inventory Drive Turnaround - Yahoo Finance
GABELLI & Co INVESTMENT ADVISERS INC. Sells 40,000 Shares of STAAR Surgical Company $STAA - MarketBeat
Why did STAAR Surgical (STAA) stock jump 20% after hours? - MSN
STAAR Surgical Q1 earnings call highlights - MSN
STAA Stock On Track For Its Fourth Straight Session Of Gains – This Analyst Would Rather Be Early Than Late On Staar’s Growth Story - Stocktwits
STAAR Surgical Co stock (US8577001096): Q1 earnings beat and rating upgrade put focus back on growth - AD HOC NEWS
Is Staar Surgical (STAA) Overvalued After Q1 2026 Earnings Beat? - GuruFocus
STAAR Surgical (NASDAQ:STAA) Upgraded at Wall Street Zen - MarketBeat
STAA Maintained by Wells Fargo -- Price Target Raised to $25.00 - GuruFocus
STAAR targets about 75% gross margin and $225M 2026 spend as Switzerland plans to supply 100% of China lenses - MSN
STAAR Surgical Company (NASDAQ:STAA) Q1 2026 Earnings Call Transcript - Insider Monkey
Staar Surgical Company stock hits 52-week high at 35.7 USD - Investing.com Canada
A Look at Staar Surgical Co (STAA) After 8.9% Gain -- GF Value $29.35 vs Price $32.01 - GuruFocus
STAAR Surgical (STAA) Sees Record Q1 Growth, Analysts Boost Pric - GuruFocus
STAA Maintained by Canaccord Genuity -- Price Target Raised to $32 - GuruFocus
STAA Maintained by Stifel -- Price Target Raised to $31.00 - GuruFocus
STAAR Surgical (STAA) Stock Soars 10% After Impressive Q1 Earnin - GuruFocus
STAA Maintains Rating by Mizuho -- Price Target Raised to $27.00 - GuruFocus
STAA Upgraded by Wedbush -- Price Target Raised to $40 - GuruFocus
STAA stock on track for its fourth straight session of gains – this analyst would rather be early than late on STAAR’s growth story - MSN
STAA Rated Neutral by Piper Sandler -- Price Target Raised to $3 - GuruFocus
Earnings To Watch: STAAR Surgical (STAA) Reports Q1 Results Tomorrow - Yahoo Finance UK
Why is STAAR Surgical stock surging today? By Investing.com - Investing.com Australia
Staar Surgical (STAA) Sees Upgrade to Outperform with Target Pri - GuruFocus
Staar Surgical Posts Upbeat Q1 Results, Joins Cisco, Yeti Holdings And Other Big Stocks Moving Higher On Thursday - Benzinga
Why is STAAR Surgical stock surging today? - Investing.com
Piper Sandler raises STAAR Surgical stock price target on Q1 beat - Investing.com Nigeria
Piper Sandler raises STAAR Surgical stock price target on Q1 beat By Investing.com - Investing.com South Africa
STAAR Surgical (NASDAQ:STAA) Given New $27.00 Price Target at Mizuho - MarketBeat
STAAR Surgical net sales up 119.6% to USD 93.5M in Q1 2026 - Medical Buyer
Staar Surgical Co Stock (STAA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):